Skip to main content

Is Leukocyte Depletion Important in the Prevention of Alloimmunization by Random Single Donor Platelet Transfusion?

  • Chapter
Advances in haemapheresis

Part of the book series: Developments in Hematology and Immunology ((DIHI,volume 25))

  • 46 Accesses

Abstract

The major risk factor associated with repeated platelet transfusions is alloimmunization. Its management represents one of the greatest remaining clinical and research challenges in the field of platelet transfusion therapy. This is particularly true because current approaches to the treatment of leukemias and various solid tumors are now focussed on the administration of intensive, repetitive courses of postremission chemotherapy necessitating successful platelet support for a prolonged time. Moreover, once alloimmunization has supervened and histocompatible donors cannot be identified there are no proven approaches for the management of bleeding complications in thrombocytopenic patients. Thus, any practical means by which the rate or the speed of alloimmunization could be minimized would be of considerable clinical importance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies. 63 administration of leukocyte-poor blood components. Exp Hematol 1981;9:77–83.

    CAS  PubMed  Google Scholar 

  2. Gmür J, von Felten A, Osterwalder B, et al. Delayed alloimmunization using random single donor platelet transfusions: A prospective study in thrombocytopenic patients with acute leukemia. Blood 1983;62:473–9:.

    PubMed  Google Scholar 

  3. Dausset J, Rapaport FT. Transplantation antigen activity of human blood platelets. Transplant 1966;4:182–93.

    Article  CAS  Google Scholar 

  4. Mincheff M, Meryman HT. Stimulation by allo-Ia requires a product of ly- sosomal processing. XII Int Cong Transplantation Soc. Sidney, 1988:177.

    Google Scholar 

  5. Marrack P, Kappler J. T-cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature 1988; 332:840–3.

    Article  CAS  PubMed  Google Scholar 

  6. Brand A, Claas FHJ, Voogt PJ, Wasser MNJM, Eernisse JG. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988;54:160–6.

    Article  CAS  PubMed  Google Scholar 

  7. Murphy MF, Metcalfe P, Thomas H, et al. Use of leukocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986;62:529–34.

    Article  CAS  PubMed  Google Scholar 

  8. Schiffer CA, Ducher JP, Aisner J, et al. Randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:15–20.

    Google Scholar 

  9. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964–9.

    CAS  PubMed  Google Scholar 

  10. Sniecinski, O’Donell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988;71:1402–7.

    CAS  PubMed  Google Scholar 

  11. Saarinen UM, Kekomäki R, Siimes MA, Myllylä G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990;75:512–7.

    CAS  PubMed  Google Scholar 

  12. Curtoni ES, Scudeller G, Mattiuz PL, Savi M, Ceppellini R. Anti-HLA-antibody evolution in recipients of planned transfusions. Tissue Antigens 1972;2:415–26.

    Article  CAS  PubMed  Google Scholar 

  13. Ferrara GB, Tosi RM, Azzolina G, Longo A. HLA unresponsiveness induced by weekly transfusions of small aliquots of whole blood. Transplant 1974;17:194–8.

    Article  CAS  Google Scholar 

  14. Slichter SJ, O’Donnell MR, Weiden PL. Canine platelet alloimmunization: The role of donor selection.Br J Haematol 1986;63:713–27.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Gmür, J., Schanz, U., Burger, J., Reichlin, M., Müller, E., Oelz, O. (1991). Is Leukocyte Depletion Important in the Prevention of Alloimmunization by Random Single Donor Platelet Transfusion?. In: Sibinga, C.T.S., Kater, L. (eds) Advances in haemapheresis. Developments in Hematology and Immunology, vol 25. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3904-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3904-9_24

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6742-0

  • Online ISBN: 978-1-4615-3904-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics